secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2026-06-02T21:20:15+00:00
Accession:  0001213900-26-064294
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech secures $2.42M additional loan from AlpineBrook; conversion price $0.08
--------------------------------------------------------------------------------

- Additional loan of $2.42M (net $2.2M after $220k fee) issued as convertible note with $0.08/sh conversion price.
- New warrant issued for shares at $0.08/exercise price, 10-year term, cashless exercise permitted.
- Consideration shares increased to 12,953,947, payable in 6 installments over 30 months from closing.
- Voting agreement with major stockholders to approve share increase within 2 months or before next financing.
- Third amendment to existing secured convertible loan; total debt now includes multiple notes and warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/0001213900-26-064294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390026064294/ea0292593-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-064294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer